GSK1940029

CAS No. 1150701-66-8

GSK1940029 ( SCD inhibitor 1 )

Catalog No. M20222 CAS No. 1150701-66-8

GSK1940029 is a stearoyl-coa desaturase (SCD) inhibitor.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 237 In Stock
10MG 357 In Stock
25MG 597 In Stock
50MG 851 In Stock
100MG 1152 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    GSK1940029
  • Note
    Research use only not for human use.
  • Brief Description
    GSK1940029 is a stearoyl-coa desaturase (SCD) inhibitor.
  • Description
    GSK1940029 is a stearoyl-coa desaturase (SCD) inhibitor.
  • Synonyms
    SCD inhibitor 1
  • Pathway
    Metabolic Enzyme/Protease
  • Target
    Dehydrogenase
  • Recptor
    SCD
  • Research Area
    Endocrinology
  • Indication
    Acne Vulgaris

Chemical Information

  • CAS Number
    1150701-66-8
  • Formula Weight
    391.25
  • Molecular Formula
    C18H16Cl2N4O2
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:30 mg/mL (76.67 mM)
  • SMILES
    Cc1c(nnn1Cc1ccc(Cl)c(Cl)c1)C(=O)Nc1ccc(CO)cc1
  • Chemical Name
    1-[(34-dichlorophenyl)methyl]-N-[4-(hydroxymethyl)phenyl]-5-methyltriazole-4-carboxamide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Anne Marie Jeanne Bouillot et al. 1 2 3-triazole derivatives for use as stearoyl-coa desaturase inhibitors . PCT Int. Appl. (2009) WO 2009060053 A1 20090514.
molnova catalog
related products
  • NSC 14613

    PluriSln 1(NSC 14613) is an inhibitor of stearoyl-coA desaturase (SCD1), the key enzyme in oleic acid biosynthesis, revealing a unique role for lipid metabolism in hPSCs.

  • PfDHODH-IN-1

    PfDHODH-IN-1 is an inhibitor of Plasmodium falciparum dihydroorotate dehydrogenase(PfDHODH) which catalyzes the rate-limiting step for DNA and RNA biosynthesis. PfDHODH-IN-1 has antimalarial activity.

  • G6PDi-1

    G6PDi-1 is an effective G6PD inhibitor. It depletes NADPH and decreases inflammatory cytokine production. G6PDi-1 effectively inhibits G6PD.